

**Errata in the  
Pharmacotherapy Self-Assessment Program, Sixth Edition (PSAP-VI)  
(Updated September 1, 2009)**

**BOOK 1 (CARDIOLOGY)**

- Page 11** Table 1-4. The metoprolol succinate daily dosing frequency in the second column should read:
- Metoprolol succinate 1  
**(Table legend should also be deleted with the deletion of the superscript in the table.)**
- Page 37** Question 40. Question should read:
- “Based on the **Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)**, what is the best response to this statement?”
- Page 65** Table 1-2. Fondaparinux column should read:
- “...IV dose of either 2.5 mg (if administered with a GP IIB/IIIA receptor inhibitor)...”
- Page 89** Table 2-2. The milrinone dose listed in the second column should be changed to the following:
- Milrinone 0.2–0.75 **mcg**/kg/minute instead of mg/kg/minute
- Page 99** Question 36. Question should read:
- “His most recent Swan-Ganz catheter readings...and **systemic vascular resistance** 600 dyne-sec/cm<sup>5</sup>...”
- Page 126** Figure 4-1. **rpta** in figure should be:
- rt-PA
- Page 126** Figure 4-1. Left-hand bottom column should read:
- “Initiate rt-PA 0.9 mg/kg maximum 90 mg”
- Page 158** Question 11. Answer A should read:
- A. Pioglitazone **15** mg/day.

## BOOK 2 (NEPHROLOGY)

### Page 3

Figure 1-1. The middle box in figure should read:

2. Measure GFR (**inulin**, iothalamate)

### Page 4

Table 1-2. <sup>a</sup> in table legend should read:

“Units are mL/minute except...”

### Page 23

Figure 2-2. The line at the bottom left of the figure should read:

“Assess for Hyporesponse (see **Figure 2-3**)”

### Page 39

Table 3-1. Second column header should read:

“Infusion Rate (mg/hour)<sup>a</sup>”

### Page 43

Figure 3-5. The X axis of the table should read, from left:

**GFR 30-59.9 ml/min/1.73 m<sup>2</sup> (n=2,876);**  
**GFR 60-89.9 ml/min/1.73 m<sup>2</sup> (n=12,333);**  
**GFR ≥ 90 ml/min/1.73 m<sup>2</sup> (n=4,491)**

### Page 70

Question 6. Question stem should read:

“Which one of the following diseases is C.J. at risk for?”

### Page 70

Question 7. Answer A should read:

- A. Stop calcium acetate. Add sevelamer **400** mg with meals.

### Page 71

Question 12. Answer C should read:

- C. Add sevelamer **400** mg by mouth 3 times/day with meals.

### Page 71

Question 15. Answer B should read:

- B. Add sevelamer **400** mg by mouth 3 times/day with meals.

### Page 72

Question 16. Answer D should read:

- C. Add Sevelamer **400** mg by mouth 3 times/day with meals.

**Page 72**

Question 20. Answer A should read:

A. Sevelamer **400** mg by mouth 3 times/day with meals.

**Page 152**

Sentence in left column, fifth line from bottom, should read:

“Gastrointestinal adverse effects tend to occur within the first 1–2 **weeks** post-transplantation.”

### **BOOK 3 (NEUROLOGY AND PSYCHIATRY)**

**Page 60**

Question 62, Answer A should read:

A. A 7% **incidence** in thrombotic complications has been reported with the use of rFVIIa.

### **BOOK 4 (SCIENCE AND PRACTICE OF PHARMACOTHERAPY)**

**Page 7**

Table 1-1 (see below) is missing.

**Table 1-1. Linear Regression Model Assumptions**

1. Existence: For each value of the independent variable, the dependent variable is random with a probability distribution that has finite mean and variance.
2. Independence: Values of the dependent variable are statistically independent from each other.
3. Linearity: The relation between the mean value of the dependent variable, given the independent variables, and the independent variables is linear.
4. Homoscedasticity: The variance of the dependent variable is the same for all levels of the independent variable.
5. Normality: For any values of the independent variable, values of the dependent variable are normally distributed.

These assumptions are generally evaluated by examining histograms, scatter plots, and graphs of residuals, which are the distance between each observation point and the regression line, among other methods.

Self-Assessment Question 37 is missing this table:

Plan	Deductible	Monthly Premium	Patient's Annual Out-of-Pocket Cost	Full Annual Drug Cost
Plan 1	\$265.00	\$31.60	\$5828	\$7971
Plan 2	\$0	\$93.20	\$2442	\$6892
Plan 3	\$75.00	\$26.10	\$4577	\$7680
Plan 4	\$0	\$17.00	\$4441	\$7887

**BOOK 5 (INFECTIOUS DISEASES)**

In Table 2-3, the values under Dose and Duration should read:

Amoxicillin	1–2 g BID
Amoxicillin/clavulanate	2 g/125 mg BID

Question 58, first full sentence in the left column should read:

“...the physician learns that the minimum inhibitory concentration of vancomycin = 4 mg/L,”

**BOOK 6 (PULMONARY/CRITICAL CARE)**

Byline should read:

“Reviewed by Jeffrey Fish, **Pharm.D., BCPS**”

Right hand column, line 23, should read:

“Fludrocortisone 50 mcg orally ...”

Stem for Question 37 should read:

“Norepinephrine was initiated at 0.2 mcg/minute”

**Page 167**

Table 3-3, second row (Dosage form) should read:

Epoprostenol	<b>Central line injectable</b>
Treprostinil	<b>Central line injectable or subcutaneous</b>
Iloprost	<b>Inhalation</b>
Bosentan	<b>Oral</b>
Ambrisentan	<b>Oral</b>
Sildenafil	<b>Oral</b>

**BOOK 7 (MEN’S AND WOMEN’S HEALTH)**

**Page 21**

Sentence in the middle of the first column should read:

“... with an increased risk of VTE compared with levonorgestrel (LNG), a **second**-generation progestin ...”

**Page 141**

Question 19 should read:

**19. Which one of the following dosages is the best vitamin D replacement for this patient?**

- A. 400 IU daily.**
- B. 600 IU daily.**
- C. 800 IU daily.**
- D. 600 IU twice daily.**

**BOOK 8 (HEALTH PROMOTION AND MAINTENANCE)**

**Page 47**

Question 41, option B should read:

“Lung cancer is the most common cause of cancer death among women.”

**Page 69**

The stem for Question 81 should read:

“The condition-specific instrument described in question **80** ...”

**Page 74**

The definition of JCPP should read:

“Joint Commission **of Pharmacy Practitioners**”

**BOOK 9 (GASTROENTEROLOGY AND NUTRITION)**

**Page 23**

The stem for Question 17 should read:

“... which laboratory test is a strong, independent risk predictor of hepatocellular carcinoma in patients like **H.B.**?”

**Page 148**

Question 33, the last option should read:

**D. Discontinue his home PN therapy immediately.**

**BOOK 10 (ONCOLOGY)**

**Page 63**

In second paragraph under “Extensive Stage”, lines 1, 7, and 25:  
“Irinotecan plus etoposide ...” should be “Irinotecan plus **cisplatin** ...”

**Page 160**

The stem should read:  
Questions 67–69 pertain to the following case.

**BOOK 11 (CHRONIC ILLNESSES)**

**Page 17**

Question 1, the stem should read:  
“ ... an initial insulin treatment plan to provide **0.5** units/kg/day. ”

**Page 56**

Question 54, the stem should read:  
“ Which one of the following is best to recommend **to prevent further decline in kidney function** at this time for K.M.?”

**Page 154**

Figure 1-1, bottom-most box on right side of algorithm:  
“Shift to another drug” should be “**Reduce dose**”